Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 333

1.

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD.

Rheumatology (Oxford). 2018 Jun 25. doi: 10.1093/rheumatology/key161. [Epub ahead of print]

PMID:
29945203
2.

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies.

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, Gottlieb AB, Gisondi P, Wu JJ, Thyssen JP, Egeberg A.

J Am Acad Dermatol. 2018 Jun 18. pii: S0190-9622(18)32149-2. doi: 10.1016/j.jaad.2018.06.027. [Epub ahead of print] Review.

PMID:
29928910
3.

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.

Deodhar A, Gottlieb AB, Boehncke WH, Dong B, Wang Y, Zhuang Y, Barchuk W, Xu XL, Hsia EC; CNTO1959PSA2001 Study Group.

Lancet. 2018 Jun 2;391(10136):2213-2224. doi: 10.1016/S0140-6736(18)30952-8. Epub 2018 Jun 1.

PMID:
29893222
4.

Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials.

Callis Duffin K, Merola JF, Christensen R, Latella J, Garg A, Gottlieb AB, Armstrong AW.

JAMA Dermatol. 2018 Jun 6. doi: 10.1001/jamadermatol.2018.1165. [Epub ahead of print]

PMID:
29874367
5.

Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting.

Gottlieb AB, Coates LC, van Mens LJJ, Armstrong AW, Merola JF.

J Rheumatol Suppl. 2018 Jun;94:40-43. doi: 10.3899/jrheum.180137.

PMID:
29858353
6.

Prologue: 2017 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

Helliwell PS, Gladman DD, Gottlieb AB.

J Rheumatol Suppl. 2018 Jun;94:1-3. doi: 10.3899/jrheum.180129.

PMID:
29858345
7.

Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled Phase 3b Study of Patients with Moderate-to-Severe Genital Psoriasis.

Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather JC, Yosipovitch G, Gottlieb AB, Merola JF, Callis Duffin K, Fretzin S, Osuntokun OO, Burge R, Naegeli AN, Yang FE, Lin CY, Todd K, Potts Bleakman A; IXORA-Q Study Group.

Br J Dermatol. 2018 May 10. doi: 10.1111/bjd.16736. [Epub ahead of print]

PMID:
29747232
8.

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results through 48 Weeks from Two Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2).

Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, Peterson L, Arendt C, Burge D, Reich K.

J Am Acad Dermatol. 2018 Apr 13. pii: S0190-9622(18)30525-5. doi: 10.1016/j.jaad.2018.04.012. [Epub ahead of print]

9.

A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process.

Thorlacius L, Ingram JR, Villumsen B, Esmann S, Kirby JS, Gottlieb AB, Merola JF, Dellavalle R, Nielsen SM, Christensen R, Garg A, Jemec GBE; HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC).

Br J Dermatol. 2018 Apr 14. doi: 10.1111/bjd.16672. [Epub ahead of print]

PMID:
29654696
10.

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.

Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, Cioffi C, Blauvelt A.

J Am Acad Dermatol. 2018 Mar 30. pii: S0190-9622(18)30491-2. doi: 10.1016/j.jaad.2018.03.037. [Epub ahead of print]

11.

The Effect of Psoriatic Arthritis on Ixekizumab Clinical Outcomes in Moderate-to-Severe Psoriasis Patients: A Post Hoc Analysis.

Gottlieb AB, Papp KA, Birbara CA, Shuler CL, Burge R, Erickson J, Kerr L, Mease PJ.

J Am Acad Dermatol. 2018 Mar 17. pii: S0190-9622(18)30458-4. doi: 10.1016/j.jaad.2018.03.008. [Epub ahead of print] No abstract available.

PMID:
29559395
12.

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.

van der Heijde D, Deodhar A, FitzGerald O, Fleischmann R, Gladman D, Gottlieb AB, Hoepken B, Bauer L, Irvin-Sellers O, Khraishi M, Peterson L, Turkiewicz A, Wollenhaupt J, Mease PJ.

RMD Open. 2018 Mar 14;4(1):e000582. doi: 10.1136/rmdopen-2017-000582. eCollection 2018. Erratum in: RMD Open. 2018 Mar 26;4(1):.

13.

Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.

Gottlieb AB, Gordon K, Hsu S, Elewski B, Eichenfield LF, Kircik L, Rastogi S, Pillai R, Israel R.

J Eur Acad Dermatol Venereol. 2018 Mar 6. doi: 10.1111/jdv.14913. [Epub ahead of print]

PMID:
29512200
14.

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.

Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ.

Br J Dermatol. 2018 Feb 28. doi: 10.1111/bjd.16464. [Epub ahead of print]

PMID:
29488226
15.

The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health.

Gottlieb AB, Kirby B, Ryan C, Naegeli AN, Burge R, Potts Bleakman A, Anatchkova MD, Cather J.

Dermatol Ther (Heidelb). 2018 Mar;8(1):33-44. doi: 10.1007/s13555-017-0212-3. Epub 2017 Dec 4.

16.

The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS).

Gottlieb AB, Kirby B, Ryan C, Naegeli AN, Burge R, Potts Bleakman A, Anatchkova MD, Yosipovitch G.

Dermatol Ther (Heidelb). 2018 Mar;8(1):45-56. doi: 10.1007/s13555-017-0213-2. Epub 2017 Dec 4.

17.

Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA × BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data.

Gottlieb AB, Merola JF, Chen R, Levi E, Duffin KC.

J Am Acad Dermatol. 2017 Dec;77(6):1178-1180. doi: 10.1016/j.jaad.2017.06.162. No abstract available.

18.

Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II.

Thorlacius L, Garg A, Ingram JR, Villumsen B, Theut Riis P, Gottlieb AB, Merola JF, Dellavalle R, Ardon C, Baba R, Bechara FG, Cohen AD, Daham N, Davis M, Emtestam L, Fernández-Peñas P, Filippelli M, Gibbons A, Grant T, Guilbault S, Gulliver S, Harris C, Harvent C, Houston K, Kirby JS, Matusiak L, Mehdizadeh A, Mojica T, Okun M, Orgill D, Pallack L, Parks-Miller A, Prens EP, Randell S, Rogers C, Rosen CF, Choon SE, van der Zee HH, Christensen R, Jemec GBE.

Br J Dermatol. 2018 Mar;178(3):715-721. doi: 10.1111/bjd.16093. Epub 2018 Feb 1.

19.

Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.

Puig L, Augustin M, Blauvelt A, Gottlieb AB, Vender R, Korman NJ, Thaçi D, Zhao Y, Gilloteau I, Sherif B, Williams N, Guana A, Lebwohl MG.

J Am Acad Dermatol. 2018 Apr;78(4):741-748. doi: 10.1016/j.jaad.2017.10.025. Epub 2017 Oct 21.

PMID:
29066271
20.

Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.

Bissonnette R, Kerdel F, Naldi L, Papp K, Galindo C, Langholff W, Tang KL, Szapary P, Fakharzadeh S, Srivastava B, Goyal K, Gottlieb AB.

J Drugs Dermatol. 2017 Oct 1;16(10):1002-1013.

PMID:
29036254
21.

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.

McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, Kajekar R, Delicha EM, Pricop L, Mpofu S.

Rheumatology (Oxford). 2017 Nov 1;56(11):1993-2003. doi: 10.1093/rheumatology/kex301.

22.

The Static Physician's Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital Psoriasis.

Merola JF, Bleakman AP, Gottlieb AB, Menter A, Naegeli AN, Bissonnette R, Guenther L, Sullivan J, Meeuwis K, See K, Duffin KC.

J Drugs Dermatol. 2017 Aug 1;16(8):793-799.

PMID:
28809994
23.

International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working Group.

Perez-Chada LM, Singh S, Callis-Duffin K, Garg A, Gottlieb AB, Latella J, Armstrong AW, Merola JF.

J Drugs Dermatol. 2017 Aug 1;16(8):770-777.

PMID:
28809992
24.

Pediatric Psoriasis Comorbidity Screening Guidelines.

Osier E, Wang AS, Tollefson MM, Cordoro KM, Daniels SR, Eichenfield A, Gelfand JM, Gottlieb AB, Kimball AB, Lebwohl M, Mehta NN, Paller AS, Schwimmer JB, Styne DM, Van Voorhees AS, Tom WL, Eichenfield LF.

JAMA Dermatol. 2017 Jul 1;153(7):698-704. doi: 10.1001/jamadermatol.2017.0499.

25.

Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study.

Egeberg A, Kristensen LE, Thyssen JP, Gislason GH, Gottlieb AB, Coates LC, Jullien D, Gisondi P, Gladman DD, Skov L, Mallbris L.

Ann Rheum Dis. 2017 Sep;76(9):1591-1597. doi: 10.1136/annrheumdis-2016-210963. Epub 2017 May 8.

PMID:
28483767
26.

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.

Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD.

Ann Rheum Dis. 2017 Sep;76(9):1550-1558. doi: 10.1136/annrheumdis-2016-210724. Epub 2017 May 4.

27.

Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting.

Callis Duffin K, Gottlieb AB, Merola JF, Latella J, Garg A, Armstrong AW.

J Rheumatol. 2017 May;44(5):701-702. doi: 10.3899/jrheum.170151.

PMID:
28461532
28.
29.

Proceedings of the GRAPPA 2016 Retreat.

Jadon DR, Gladman DD, Mease PJ, FitzGerald O, Chandran V, Goel N, Rosen CF, Maksymowych WP, Ritchlin CT, Ogdie A, Coates LC, Cauli A, Soriano ER, Husni ME, Campbell W, Azevedo VF, Callis Duffin K, Armstrong AW, Gottlieb AB, Kavanaugh A, Garg A, Helliwell PS.

J Rheumatol. 2017 May;44(5):668-673. doi: 10.3899/jrheum.170141.

PMID:
28461522
30.

Prologue: 2016 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

Helliwell PS, Gladman DD, Gottlieb AB.

J Rheumatol. 2017 May;44(5):658-660. doi: 10.3899/jrheum.170139.

PMID:
28461520
31.

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib.

Rothstein B, Joshipura D, Saraiya A, Abdat R, Ashkar H, Turkowski Y, Sheth V, Huang V, Au SC, Kachuk C, Dumont N, Gottlieb AB, Rosmarin D.

J Am Acad Dermatol. 2017 Jun;76(6):1054-1060.e1. doi: 10.1016/j.jaad.2017.02.049. Epub 2017 Apr 5.

PMID:
28390737
32.
33.

The International Dermatology Outcome Measures (IDEOM) Initiative: A Review and Update.

Elman SA, Merola JF, Armstrong AW, Duffin KC, Latella J, Garg A, Gottlieb AB.

J Drugs Dermatol. 2017 Feb 1;16(2):119-124. Review.

PMID:
28300853
34.

Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes.

Thorlacius L, Ingram JR, Garg A, Villumsen B, Esmann S, Kirby JS, Gottlieb AB, Merola JF, Dellavalle R, Christensen R, Jemec GB.

BMJ Open. 2017 Feb 20;7(2):e014733. doi: 10.1136/bmjopen-2016-014733.

35.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.

Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, Gnanasakthy A, Papavassilis C, Lebwohl MG.

J Am Acad Dermatol. 2017 Apr;76(4):655-661. doi: 10.1016/j.jaad.2016.11.043. Epub 2017 Jan 10.

PMID:
28087133
36.

Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.

van de Kerkhof P, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, Morita A, Goldblum O, Zhang L, Erickson J, Ball S, Rich P.

J Eur Acad Dermatol Venereol. 2017 Mar;31(3):477-482. doi: 10.1111/jdv.14033. Epub 2016 Dec 2.

PMID:
27910156
37.

From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis.

Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, Callis Duffin K, Eichenfield LF, Garg A, Gelfand JM, Gottlieb AB, Koo JY, Korman NJ, Krueger GG, Lebwohl MG, Leonardi CL, Mandelin AM, Menter MA, Merola JF, Pariser DM, Prussick RB, Ryan C, Shah KN, Weinberg JM, Williams MO, Wu JJ, Yamauchi PS, Van Voorhees AS.

J Am Acad Dermatol. 2017 Feb;76(2):290-298. doi: 10.1016/j.jaad.2016.10.017. Epub 2016 Nov 28. Review.

38.

Psoriasis.

Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, Mehta NN, Finlay AY, Gottlieb AB.

Nat Rev Dis Primers. 2016 Nov 24;2:16082. doi: 10.1038/nrdp.2016.82. Review.

PMID:
27883001
39.

Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.

Gottlieb AB, Lacour JP, Korman N, Wilhelm S, Dutronc Y, Schacht A, Erickson J, Zhang L, Mallbris L, Gerdes S.

J Eur Acad Dermatol Venereol. 2017 Apr;31(4):679-685. doi: 10.1111/jdv.13990. Epub 2016 Nov 2.

40.

Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis.

Rahman P, Puig L, Gottlieb AB, Kavanaugh A, McInnes IB, Ritchlin C, Li S, Wang Y, Song M, Mendelsohn A, Han C; PSUMMIT 1 and 2 Study Groups.

Arthritis Care Res (Hoboken). 2016 Dec;68(12):1812-1822. doi: 10.1002/acr.23000. Epub 2016 Oct 21.

41.

Candida Esophagitis Associated With Mycophenolate Mofetil Treatment of Atopic Dermatitis.

Kurayev A, Gottlieb AB.

J Drugs Dermatol. 2016 Oct 1;15(10):1267-1269.

PMID:
27741346
42.

Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.

Gottlieb AB, Blauvelt A, Prinz JC, Papanastasiou P, Pathan R, Nyirady J, Fox T, Papavassilis C.

J Drugs Dermatol. 2016 Oct 1;15(10):1226-1234.

PMID:
27741340
43.

Hidradenitis Suppurativa: Review of the Pathogenesis and Treatment.

Kurayev A, Ashkar H, Saraiya A, Gottlieb AB.

J Drugs Dermatol. 2016 Aug 1;15(8):1017-22. Review.

PMID:
27538005
44.

Effect of Psoriatic Arthritis on Treatment Response in Patients With Moderate to Severe Psoriasis.

Greb JE, Garber C, Gottlieb AB.

J Drugs Dermatol. 2016 Aug 1;15(8):917-22.

PMID:
27537990
45.

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiai Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB.

N Engl J Med. 2016 Aug 4;375(5):422-34. doi: 10.1056/NEJMoa1504370.

46.

High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum.

Greb JE, Gottlieb AB, Goldminz AM.

Dermatol Ther. 2016 Nov;29(6):482-483. doi: 10.1111/dth.12387. Epub 2016 Aug 9. No abstract available.

PMID:
27502191
47.

Insights on methotrexate in psoriatic disease.

Greb JE, Goldminz AM, Gottlieb AB.

Clin Immunol. 2016 Nov;172:61-64. doi: 10.1016/j.clim.2016.07.008. Epub 2016 Jul 25.

PMID:
27455859
48.

Psoriasis Trends and Practice Gaps.

Gottlieb AB, Greb JE, Goldminz AM.

Dermatol Clin. 2016 Jul;34(3):235-42. doi: 10.1016/j.det.2016.03.004. Review.

PMID:
27363878
49.

Apremilast and Secukinumab Combined Therapy in a Patient With Recalcitrant Plaque Psoriasis.

Rothstein BE, McQuade B, Greb JE, Goldminz AM, Gottlieb AB.

J Drugs Dermatol. 2016 May 1;15(5):648-9.

PMID:
27168275
50.

The Psoriatic Disease Payer Advisory Panel.

Greb JE, Merola J, Garg A, Latella J, Howard L, Acharya N, Gottlieb AB.

J Drugs Dermatol. 2016 May 1;15(5):641-4. Review.

PMID:
27168273

Supplemental Content

Loading ...
Support Center